Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors

  • End date
    Dec 9, 2023
  • participants needed
  • sponsor
    OBI Pharma, Inc
Updated on 4 October 2022


The purpose of this study is to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of OBI-999 as monotherapy, and to characterize the safety and preliminary clinical activity profile of the RP2D of OBI-999 in patients with advanced solid tumors.

Condition Locally Advanced Solid Tumor
Treatment OBI-999
Clinical Study IdentifierNCT04084366
SponsorOBI Pharma, Inc
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Male or female patients, 18 years of age or older at the time of consent
Provide written informed consent prior to performing any study related procedure
Histologically or cytologically confirmed patients with advanced solid tumors
Patients must have been treated with established standard-of-care therapy, or physicians have determined that such established therapy is not sufficiently efficacious, or patients have declined to receive standard-of-care therapy. In the latter case, the informed consent must state the effective therapies the patient is declining
Measurable disease (i.e., at least one measurable lesion per RECIST 1.1)
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate organ function defined as
Serum ALT ≤3 × upper limit of normal (ULN), ≤5 × ULN in the presence of liver metastases
ii. Serum AST ≤3 × ULN, ≤5 × ULN in presence of liver metastases
iii.Serum bilirubin ≤1.5 × ULN (unless due to Gilbert's syndrome or hemolysis)
b. Renal
i. Creatinine clearance >50 mL/minute using Cockcroft Gault equation
c. Hematologic
i. Absolute neutrophil count ≥1,500/µL
ii. Platelets ≥100,000/µL
iii. Hemoglobin ≥8 g/dL
Patient is willing and able to comply with all protocol required assessments, visits
and procedures, including a pretreatment tumor biopsy. Archival tumor biopsies are
acceptable at baseline
Females of childbearing potential must have negative serum pregnancy test prior to
starting study therapy, and agree to use a reliable form of contraceptive during the
study treatment period and for at least 120 days following the last dose of study
Patient not of childbearing potential (i.e., permanently sterilized, postmenopausal)
can be included in study. Postmenopausal is defined as 12 months with no menses
without an alternative medical cause
Male patients must agree to use an adequate method of contraception during the study
treatment period and for at least 120 days following the last dose of study drug
Cannot be breast feeding
Patients with human immunodeficiency virus (HIV) infection are eligible if CD4+ T cell
counts ≥ 350 cells/uL; patients on antiretroviral therapy (ART) should be on an
established dose for at least 4 weeks and have an HIV viral load less than 400
copies/mL prior to enrollment
Patients with serological evidence of chronic hepatitis B virus (HBV) infection are
eligible if they have an HBV viral load below the limit of quantification with or
without concurrent viral suppressive therapy
Patients with a history of hepatitis C virus (HCV) infection should have completed
curative antiviral treatment and have a viral load below the limit of quantification
Patients in Part B (Cohort-Expansion) must have documented Globo H H score of at least
from a qualified laboratory IHC assay in one of the sponsor-selected tumor types
to be enrolled in the respective cohort
Cohort 1: Pancreatic cancer
Cohort 2: Esophageal cancer
Cohort 3: Gastric cancer
Cohort 5: Basket (any solid tumor type other than those included in Cohorts 1
Cohort 4: Colorectal cancer
through 4)

Exclusion Criteria

Less than 3 weeks from prior cytotoxic chemotherapy or radiation therapy; and less
than 5 half-lives or 3 weeks, whichever is shorter, from prior biologic therapies
prior to the first dose of OBI 999
Sensory or motor neuropathy of Grade 2 or greater
Has undergone a major surgical procedure (as defined by the Investigator) or
Patients with a history of solid organ transplant
significant traumatic injury within 28 days prior to the first dose of OBI 999
Receipt of any prior therapy targeting Globo H
Known hypersensitivity to OBI 999 or its excipients
Unresolved toxicities from prior anticancer therapy, defined as having not resolved to
Grade 0 or 1 (using NCI CTCAE version 5.0), except for alopecia and laboratory values
listed in the inclusion criteria
Is receiving any concurrent prohibited medication
Has known untreated central nervous system metastases. Patients with treated brain
metastases are eligible if there is no evidence of progression for at least 4 weeks
after CNS-directed treatment, as ascertained by clinical examination and brain imaging
(magnetic resonance imaging [MRI] or computed tomography [CT]) during the screening
Has significant clinical cardiac abnormality (e.g., clinical heart failure or unstable
Any medical co morbidity that is life threatening or, in the opinion of the
Investigator, renders the patient unsuitable for participation in a clinical trial due
to possible noncompliance, would place the patient at an unacceptable risk and/or
potential to affect interpretation of results of the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note